Axonics, Inc. Stock: price and insider trades · United States

Commercially, Axonics focused primarily on the United States, where it built its initial footprint through direct commercialization and physician engagement, while also expanding internationally through regulatory approvals and market access efforts. In its 2024 disclosures, management highlighted continued revenue growth driven by higher utilization among existing sacral neuromodulation customers and the onboarding of new accounts. That operating momentum mattered because Axonics competed in a market dominated by a small number of highly specialized medtech players, where product durability, patient convenience, MRI compatibility, and surgeon / urologist support can be decisive competitive factors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/axnx-03312024xex991.htm?utm_source=openai))

The most important recent event was the acquisition by Boston Scientific, completed on November 15, 2024. The transaction followed a merger agreement announced in January 2024 and subsequent regulatory review. For investors analyzing SEC Form 4 insider activity, the key contextual point is that Axonics ceased to be an independent public company after the closing of that deal; AXNX was no longer a standalone Nasdaq-listed equity once the acquisition was completed. In practical terms, any historical insider transaction analysis should therefore be interpreted in the context of a company that has already been taken private by a strategic acquirer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1603756/000160375624000048/axnx-20240403.htm?utm_source=openai))